<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in the world; the main cause of <z:hpo ids='HP_0011420'>death</z:hpo> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e>, which can be treated with <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> using isolated hepatic perfusion (IHP) </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we report that mild <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> potently reduced cellular FLIP(long), (c-FLIPL), a major regulator of the <z:hpo ids='HP_0011420'>death</z:hpo> receptor (DR) pathway of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, thereby enhancing humanized anti-DR4 antibody mapatumumab (Mapa)-mediated mitochondria-independent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>We observed that overexpression of c-FLIPL in CX-1 cells abrogated the synergistic effect of Mapa and <z:hpo ids='HP_0001945'>hyperthermia</z:hpo>, whereas silencing of c-FLIP in CX-1 cells enhanced Mapa-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001945'>Hyperthermia</z:hpo> altered c-FLIPL protein stability without concomitant reductions in FLIP <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Ubiquitination of c-FLIPL was increased by <z:hpo ids='HP_0001945'>hyperthermia</z:hpo>, and <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> MG132 prevented heat-induced downregulation of c-FLIPL </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest the involvement of the ubiquitin-proteasome system in this process </plain></SENT>
<SENT sid="6" pm="."><plain>We also found <z:chebi fb="0" ids="32568">lysine residue</z:chebi> 195 (K195) to be essential for c-FLIPL ubiquitination and proteolysis, as mutant c-FLIPL lysine 195 arginine (arginine replacing lysine) was left virtually un-ubiquitinated and was refractory to <z:hpo ids='HP_0001945'>hyperthermia</z:hpo>-triggered degradation, and thus partially blocked the synergistic effect of Mapa and <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Our observations reveal that <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> transiently reduced c-FLIPL by proteolysis linked to K195 ubiquitination, which contributed to the synergistic effect between Mapa and <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>This study supports the application of <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> combined with other regimens to treat colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> </plain></SENT>
</text></document>